Authors
Latest:
Integrative Oncology in Young Women With Breast CancerYancey Warren, Jr, MD, MAT, and colleagues investigate the use of integrative oncology services among young women with breast cancer.
Latest:
Metastatic Renal Cell Carcinoma With Sarcomatoid FeaturesIn this installement of Clinical Quandaries, Abigail Mateos-Soria, MD, and colleagues present a case of an 38-year-old woman who has a 3-month history of fatigue, dyspnea, significant weight loss, and severe left flank pain.
Latest:
Best Practices for Referring Patients for CAR T TherapyPanelists discuss the growing importance of early integration and collaboration between community oncologists and specialized centers in the evolving chimeric antigen receptor (CAR) T-cell therapy landscape for multiple myeloma, emphasizing timely referrals, coordinated care, and strategic sequencing with other immunotherapies to optimize patient outcomes.
Latest:
Which Larynx-Preservation Strategy Would Be Best for a Patient With Resectable, Locally Advanced, Hypopharynx Squamous Cell Carcinoma?A 57-year-old man with a heavy smoking and alcohol consumption history, but no comorbidities, presented with pharyngeal pain to his primary care physician’s office. He received empirical treatment with oral antibiotics and experienced partial improvement. A couple of months later, he developed a left cervical mass with progressive growth. A head and neck CT scan revealed a hypopharyngeal tumor. Results of a tumor biopsy indicated an ulcerated, moderately differentiated squamous cell carcinoma (SCC) with lymphovascular invasion. The patient was sent to our institution for treatment.
Latest:
Ira Winer, MD, PhD, Discusses Next Steps for Nemvaleukin Alfa Plus Pembrolizumab in Ovarian CancerIra Winer, MD, PhD, FACOG, spoke about future directions of nemvaleukin alfa plus pembrolizumab for patients with pretreated platinum resistant ovarian cancer.
Latest:
Data Support Niraparib Combo as First-Line Maintenance in Ovarian CancerFindings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Latest:
Advancing Biomedical Research on Salivary Antioxidants: Exploring the Significance in Oral Precancer and CancerHuman saliva may hold antioxidants that are able to monitor the oral cavity's oxidative processes and offer guidance for the development of new drugs.
Latest:
Molecular Diagnostics, PIPAC Appear "Exciting" in GI Cancer Surgical CareSpatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Latest:
Elevating the Quality of Cancer Care via Cross-Department CollaborationExperts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.
Latest:
Evolving Landscape of HR+ Metastatic Breast Cancer ManagementClosing out their review of treatment strategies for HR+ metastatic breast cancer, a panel of experts highlights ongoing investigations and future directions in care.
Latest:
Future Directions in Advanced RCCPanelists discuss future directions in the treatment of advanced renal cell carcinoma (RCC), focusing on emerging therapies, clinical trials, and potential advancements in patient disease management.
Latest:
Squamous Cell Carcinoma of the Kidney: A Large Case SeriesSyed Arslan Shehzad Shah, MD, and colleagues present findings from a broad investigation into this rare neoplasm of the kidney, including data on patient demographics and mean survival.
Latest:
Key CAR T and Transplantation Presentations From The 2025 Tandem MeetingShernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.
Latest:
Molecular Profiling in Metastatic Colorectal CancerABSTRACT: Colorectal cancer (CRC) is a commonly diagnosed malignancy. Although chemotherapy remains the backbone of treatment, the landscape of treating metastatic CRC (mCRC) is changing with the understanding of its heterogeneity and molecular blueprint. Colon cancer sidedness has proven to hold prognostic implications, with right-sided tumors having higher incidence of BRAF and KRAS mutations and being microsatellite instability–high (MSI-H); overall, they have a worse prognosis compared with left sided-tumors. Results of molecular research have demonstrated the need to profile each mCRC patient for RAS and BRAF mutations, MSI-H status, HER2 amplifications, and NTRK fusions. Ongoing clinical trials using targeted agents aim to further improve survival outcomes. We emphasize the epidemiology, knowledge of primary tumor location, and mutational landscape of mCRC, as well as novel treatment options for patients harboring unique subtypes of these characteristics.
